Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Pesquisa Study Connect
  • NCT06045689

Recruiting

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants - CA056-1060

Atualizado: 17 dezembro, 2024   |   ClinicalTrials.gov

Imprima o Resumo

CONSIDERANDO ESTE ESTUDO?
Imprima esta página e o guia de estudo para ajudá-lo a conversar com seu médico.
Use o guia de estudo para navegar no processo de participação em um estudo clínico. Entenda os principais fatores a serem considerados antes de decidir e faça perguntas para sua equipe de saúde.
Imprimir esta página CA056-1060
Baixar o guia

SELECIONAR IDIOMA

Detalhes do estudo

  • Phase 3

    Fase

  • Gênero(s)

  • 18+

    Faixa etária

  • 45

    Localização(ões)

  • Recruiting

Opções de tratamento

Braços de tratamento do Estudo
INTERVENÇÃO ATRIBUÍDA
Experimental: Cohort 1: erythropoiesis-stimulating agents (ESA) naïve
Drug: Luspatercept
Experimental: Cohort 2: ESA relapsed or refractory
Drug: Luspatercept

Principais critérios de elegibilidade

Inclusion Criteria: - Participant had documented diagnosis of MDS according to World Health Organization (WHO) classification that met Revised International Prognostic Scoring System (IPSS-R) classification of very low-, low-, or intermediate-risk disease. - Participant has an Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2. - Participant must have red blood cell transfusions according to study criteria. Exclusion Criteria: - Participant has known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding. - Participant has had a prior allogeneic or autologous stem cell transplant. - Participant has known history or diagnosis of AML. - Participant has uncontrolled hypertension. Other protocol-defined inclusion/exclusion criteria apply

É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas

Tem dúvidas? Envie-nos um email.

Tem dúvidas?
Envie-nos um email.